Top Markets
#1 QuantixAI QuantixAI +105.36%
#2 龙虾 (Lobster) 龙虾 (Lobster) +70.95%
#3 Pons Pons +31.22%
#4 MetaDAO MetaDAO +28.82%
#5 Rain Rain +22.55%
#6 Bedrock Bedrock +21.25%
#7 Ontology Gas Ontology Gas +17.40%
#8 Prom Prom +14.68%
#9 Humanity Humanity +14.44%
#10 Stacks Stacks +13.98%
Coin of the day
QuantixAI QuantixAI
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Adagene Inc. Adagene Inc.

Adagene Inc.

ADAG
Classifica tra le azioni #19938
Adagene Inc. functions as a clinical-stage biopharmaceutical organization,... Adagene Inc. functions as a clinical-stage biopharmaceutical organization, primarily concentrating on the identification, evolution, and fabrication of monoclonal antibody-based therapeutics engineered to combat various types of cancer. The company's developmental pipeline encompasses several investigational assets currently undergoing human trials. Among these is ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibody, which is navigating Phase 1b/2 clinical assessment for individuals with advanced solid tumors and non-Hodgkin's lymphoma. Additionally, Adagene is progressing ADG126, a fully-human anti-CTLA-4 mAb, and ADG116, another human ligand-blocking anti-CTLA-4 mAb, both of which are advancing through Phase 1 studies for the treatment of advanced or metastatic solid tumors. Further along, ADG104, an anti-PD-L1 mAb, is in Phase 2 clinical development, and the innovative anti-CSF-1R mAb, ADG125, is undergoing Phase 1 trials. Beyond its clinical-stage programs, the firm also maintains an active preclinical portfolio. This includes ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is being explored for hematologic and solid tumor indications; ADG138, a novel HER2xCD3 POWERbody designed to target HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody under investigation for its potential to minimize off-tumor toxicities. Adagene Inc. was founded in 2011 and its principal operations are based in Suzhou, China.
Prezzo delle azioni
$3.88
Capitalizzazione di mercato
$146.08M
Variazione (1 giorno)
-0.51%
Variazione (1 anno)
65.11%
Paese
CN
Scambia Adagene Inc. (ADAG)

Categoria

Healthcare
Storico del rendimento da dividendi per Adagene Inc. (ADAG)
Il rendimento da dividendi (TTM) di Adagene Inc. (simbolo azionario: ADAG) al 2026 è: 0
Rendimento medio negli ultimi 5 anni: 0.00%
Storico del rendimento da dividendi per Adagene Inc. (ADAG) da 2026 a 2026
Rendimento da dividendi alla fine di ogni anno (TTM)
Anno Rendimento da dividendi Cambia
Non abbastanza dati per le date fornite.
Rendimenti da dividendi (TTM) di aziende simili o concorrenti
Azienda Rendimento da dividendi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
3.12%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH